Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - James Hardie Industries plc is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Allegations and Stock Performance - The lawsuit claims that James Hardie misrepresented the strength and momentum of its North American fiber cement segment, asserting that sales were driven by sustainable customer demand rather than inventory loading by channel partners [5]. - On August 19, 2025, James Hardie disclosed a 12% decline in North American fiber cement sales, attributed to destocking efforts by customers, leading to a stock price drop of over 34%, from $28.43 to $18.64 per share [6]. Legal Proceedings - Investors have until December 23, 2025, to request to lead the case in the U.S. District Court for the Northern District of Illinois, with the case titled Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc, et al. [3]. Management Changes - On November 17, 2025, it was announced that Rachel Wilson would step down from her role as CFO of James Hardie [7].

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws. If you invested in Freeport, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/freeport-mcmoran-inc-clas ...

Core Points - Rosen Law Firm is reminding purchasers of aTyr Pharma, Inc. common stock about the lead plaintiff deadline for a class action lawsuit, which is December 8, 2025 [1][3] - Investors who purchased aTyr Pharma stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Company Details - The lawsuit claims that aTyr Pharma provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [5] - The firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]

AVTR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Avantor, Inc. Investors Share NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Avantor, Inc. ("Avantor†or the "Company†) (NYSE:AVTR) securities during the period of March 5, 2024 through October 28, 2025, inclusive ("the Class Period†). If you suffered a loss on your Avantor investments, you have until Decemb ...

Core Viewpoint - The lawsuit against Primo Brands Corporation alleges that the company misled investors regarding the successful integration of its merger, which was actually fraught with significant operational issues, leading to a substantial decline in stock value [2][4][9]. Allegations and Facts - The lawsuit claims that executives of Primo Brands assured investors that the merger was progressing well and would enhance growth, despite the existence of undisclosed technological and service problems [4][9]. - The situation escalated when, on November 6, 2025, the company announced a leadership change, including the replacement of its CEO, and acknowledged that they had "probably moved too far too fast" in the integration process, confirming operational failures [5][9]. - Following this disclosure, the stock price plummeted by approximately 36%, reflecting the market's reaction to the revealed extent of the company's operational issues and the need to revise revenue forecasts for 2025 [5][9]. Legal Context - The class action lawsuit is focused on whether Primo Brands violated federal securities laws by making false or misleading statements that inflated its stock price during the class period, which spans from June 17, 2024, to November 6, 2025 [6][9]. - Investors who purchased securities of Primo Brands or its predecessor during the class period and experienced losses may be eligible to serve as Lead Plaintiff, with a deadline for filing set for January 12, 2026 [7][9].

Core Viewpoint - A class action lawsuit has been filed against DeFi Technologies on behalf of investors who acquired its securities during the specified class period, alleging misleading statements and failure to disclose critical business challenges [1][2]. Summary by Sections Lawsuit Details - The lawsuit claims that DeFi Technologies faced delays in executing its DeFi arbitrage strategy, which was a key revenue driver [2]. - It is alleged that the company understated the competition from other digital asset treasury companies, impacting its ability to execute its strategy [2]. - The lawsuit also states that DeFi was unlikely to meet its previously issued revenue guidance for fiscal year 2025 due to these issues [2]. Financial Impact - On November 6, 2025, DeFi reported a decline in share price by approximately 7.43%, dropping from $1.75 to $1.62 following a press release about arbitrage trade delays [3]. - On November 14, 2025, DeFi announced a nearly 20% revenue decline, significantly lowering its 2025 revenue forecast from $218.6 million to approximately $116.6 million, attributing this to delays in executing arbitrage opportunities [4]. - Following this announcement, DeFi's share price fell by approximately 14.63%, from $1.23 to $1.05 [4]. Investor Actions - Investors who suffered losses on their DeFi investments have until January 20, 2026, to request lead plaintiff appointment in the class action lawsuit [2][5]. - The lead plaintiff appointment process allows investors with the largest financial loss to represent the class, influencing case strategy and settlement decisions [5].

Accessibility StatementSkip Navigation NEW YORK, Dec. 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Molina Healthcare, Inc. (NYSE: MOH) between February 5, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), of the important December 2, 2025 lead plaintiff deadline. So What: If you purchased Molina securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs thr ...

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a securities class action lawsuit due to regulatory setbacks and significant stock declines, prompting an investigation into potential securities fraud [1][6]. Summary by Relevant Sections Class Action Details - The class action lawsuit, titled Thomas v. Telix Pharmaceuticals Ltd., aims to represent investors who purchased the company's securities between February 21, 2025, and August 28, 2025 [2]. - The lawsuit alleges that Telix and its executives made false and misleading statements about the company's business, inflating its valuation before the truth was revealed [2]. Core Allegations - The lawsuit claims Telix violated the Securities Exchange Act of 1934 by failing to disclose critical information regarding regulatory issues [3]. - Two major events led to a significant decline in Telix's American Depositary Shares (ADSs): 1. The FDA issued notices of deficiency to third-party manufacturing partners, contradicting earlier assurances about supply chain reliability [3]. 2. Following this news, Telix's ADSs dropped over 21% in value over two trading sessions [4]. Specific Misrepresentations - Management allegedly overstated the progress and commercial prospects of prostate cancer therapeutic candidates TLX591 and TLX592 [5]. - The company misrepresented the stability and regulatory compliance of its third-party supply chain, which was crucial for regulatory applications [5]. Regulatory Events Impacting Stock - The first significant stock drop occurred after Telix disclosed receiving a subpoena from the SEC on July 22, 2025, leading to a more than 13% decline in ADS price over two trading sessions [5]. - The second major blow came on August 28, 2025, when Telix received a Complete Response Letter from the FDA for TLX250-CDx, identifying deficiencies in the Chemistry, Manufacturing, and Controls package [5]. Investigation and Legal Proceedings - Hagens Berman is actively investigating the claims, focusing on discrepancies between the company's assurances and the regulatory revelations [7]. - The firm is looking into whether Telix knowingly misrepresented its drug development and manufacturing capabilities [7].

Core Viewpoint - A class action lawsuit has been filed against StubHub Holdings, Inc. for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves allegations against StubHub and certain officers and/or directors regarding securities fraud [2]. - Investors have until January 23, 2026, to request to be appointed as Lead Plaintiff if they purchased StubHub securities during the Class Period [2]. Group 2: Financial Performance - StubHub conducted its IPO on September 17, 2025, offering 34,042,553 shares at $23.50 per share [4]. - The company reported a negative free cash flow of $4.6 million for Q3 2025, a 143% decrease from the previous year's positive free cash flow of $10.6 million [4]. - Net cash provided by operating activities was $3.8 million, down 69.3% from $12.4 million in the same period last year [4]. - Following the financial results announcement, StubHub's stock price dropped by $3.95, or 20.9%, closing at $14.87 per share on November 14, 2025 [4].

Core Viewpoint - Synopsys, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - A class action lawsuit has been filed against Synopsys and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until December 30, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Northern District of California [3]. Group 2: Company Performance and Allegations - Synopsys provides design automation software products, with its Design IP segment being the fastest-growing, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. - The company previously claimed that customers relied on its IP to minimize integration risk and speed time to market, while also stating strength in Europe and South Korea [5]. - Allegations suggest that customers began requiring more customization for IP components, negatively impacting the economics of the Design IP business and jeopardizing the business model [5]. Group 3: Financial Impact - On September 9, 2025, Synopsys reported Q3 2025 results, revealing a 7.7% year-over-year decline in revenue for the Design IP segment, totaling $425.9 million, and a 43% year-over-year decline in net income, amounting to $242.5 million [6]. - Following the release of these results, Synopsys stock fell nearly 36%, from $604.37 per share to $387.78 per share within a day [6].